Literature DB >> 33926067

Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target.

Young Ha Ahn1,2, Se-Chan Oh2,3, Shengtao Zhou1, Tae-Don Kim2,3.   

Abstract

Tryptophanyl-tRNA synthetase (WRS) is an essential enzyme that catalyzes the ligation of tryptophan (Trp) to its cognate tRNAtrp during translation via aminoacylation. Interestingly, WRS also plays physiopathological roles in diseases including sepsis, cancer, and autoimmune and brain diseases and has potential as a pharmacological target and therapeutic. However, WRS is still generally regarded simply as an enzyme that produces Trp in polypeptides; therefore, studies of the pharmacological effects, therapeutic targets, and mechanisms of action of WRS are still at an emerging stage. This review summarizes the involvement of WRS in human diseases. We hope that this will encourage further investigation into WRS as a potential target for drug development in various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.

Entities:  

Keywords:  Alzheimer’s disease; IFN-γ; cancer; kynurenine pathway; sepsis; tryptophan metabolism; tryptophanyl-tRNA synthetase

Year:  2021        PMID: 33926067     DOI: 10.3390/ijms22094523

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  88 in total

Review 1.  Interferons as antiangiogenic agents.

Authors:  Daniel J Lindner
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

Review 2.  Aminoacyl-tRNA synthetase complexes: beyond translation.

Authors:  Sang Won Lee; Byeong Hoon Cho; Sang Gyu Park; Sunghoon Kim
Journal:  J Cell Sci       Date:  2004-08-01       Impact factor: 5.285

3.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Analysis of gene expression during maturation of immature dendritic cells derived from peripheral blood monocytes.

Authors:  T Matsunaga; T Ishida; M Takekawa; S Nishimura; M Adachi; K Imai
Journal:  Scand J Immunol       Date:  2002-12       Impact factor: 3.487

5.  A human aminoacyl-tRNA synthetase as a regulator of angiogenesis.

Authors:  Keisuke Wakasugi; Bonnie M Slike; John Hood; Atsushi Otani; Karla L Ewalt; Martin Friedlander; David A Cheresh; Paul Schimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

6.  Evolution of function of a fused metazoan tRNA synthetase.

Authors:  Partho Sarothi Ray; James C Sullivan; Jie Jia; John Francis; John R Finnerty; Paul L Fox
Journal:  Mol Biol Evol       Date:  2010-09-09       Impact factor: 16.240

Review 7.  Functional expansion of human tRNA synthetases achieved by structural inventions.

Authors:  Min Guo; Paul Schimmel; Xiang-Lei Yang
Journal:  FEBS Lett       Date:  2010-01-21       Impact factor: 4.124

8.  Tryptophanyl-tRNA synthetase is a major soluble protein species in bovine pancreas.

Authors:  M L Sallafranque; M Garret; J P Benedetto; M Fournier; B Labouesse; J Bonnet
Journal:  Biochim Biophys Acta       Date:  1986-06-19

9.  Aminoacyl-tRNA synthetase deficiencies in search of common themes.

Authors:  Imre F Schene; Gautam Kok; Sabine A Fuchs; Jurriaan M Jansen; Peter G J Nikkels; Koen L I van Gassen; Suzanne W J Terheggen-Lagro; Saskia N van der Crabben; Sanne E Hoeks; Laetitia E M Niers; Nicole I Wolf; Maaike C de Vries; David A Koolen; Roderick H J Houwen; Margot F Mulder; Peter M van Hasselt
Journal:  Genet Med       Date:  2018-06-06       Impact factor: 8.822

Review 10.  Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.

Authors:  Lijie Zhai; April Bell; Erik Ladomersky; Kristen L Lauing; Lakshmi Bollu; Jeffrey A Sosman; Bin Zhang; Jennifer D Wu; Stephen D Miller; Joshua J Meeks; Rimas V Lukas; Eugene Wyatt; Lynn Doglio; Gary E Schiltz; Robert H McCusker; Derek A Wainwright
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 8.786

View more
  1 in total

1.  MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.

Authors:  Masayuki Hagiwara; Atsushi Fushimi; Atrayee Bhattacharya; Nami Yamashita; Yoshihiro Morimoto; Mototsugu Oya; Henry G Withers; Qiang Hu; Tao Liu; Song Liu; Kwok K Wong; Mark D Long; Donald Kufe
Journal:  Oncoimmunology       Date:  2022-02-01       Impact factor: 7.723

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.